Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)‘s stock had its “buy” rating restated by research analysts at Canaccord Genuity in a note issued to investors on Monday. They currently have a $522.00 target price on the biopharmaceutical company’s stock. Canaccord Genuity’s target price points to a potential upside of 20.43% from the stock’s current price.

REGN has been the subject of several other research reports. BMO Capital Markets increased their price objective on shares of Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the company a “hold” rating in a research note on Monday, May 15th. Morgan Stanley reiterated an “equal weight” rating and issued a $450.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 23rd. Leerink Swann reiterated an “outperform” rating and issued a $580.00 price objective (up previously from $573.00) on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 9th. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 14th. Finally, Citigroup Inc. increased their price objective on shares of Regeneron Pharmaceuticals from $555.00 to $575.00 and gave the company a “buy” rating in a research note on Friday, August 4th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $491.43.

Regeneron Pharmaceuticals (NASDAQ REGN) traded down 1.77% during trading on Monday, reaching $433.45. The company had a trading volume of 1,002,422 shares. The company has a 50-day moving average price of $472.80 and a 200 day moving average price of $445.37. The company has a market capitalization of $45.96 billion, a price-to-earnings ratio of 43.48 and a beta of 1.65. Regeneron Pharmaceuticals has a one year low of $325.35 and a one year high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.50. The firm had revenue of $1.47 billion during the quarter, compared to analyst estimates of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The company’s revenue for the quarter was up 21.2% on a year-over-year basis. During the same quarter last year, the business posted $2.82 EPS. Analysts expect that Regeneron Pharmaceuticals will post $14.90 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Canaccord Genuity Reaffirms Buy Rating for Regeneron Pharmaceuticals, Inc. (REGN)” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/17/canaccord-genuity-reaffirms-buy-rating-for-regeneron-pharmaceuticals-inc-regn.html.

In other news, Chairman P Roy Vagelos sold 1,305 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $470.00, for a total transaction of $613,350.00. Following the completion of the sale, the chairman now directly owns 329,543 shares of the company’s stock, valued at approximately $154,885,210. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Michael S. Brown sold 3,000 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, June 20th. The stock was sold at an average price of $500.00, for a total transaction of $1,500,000.00. Following the sale, the director now directly owns 3,000 shares of the company’s stock, valued at $1,500,000. The disclosure for this sale can be found here. Over the last three months, insiders sold 99,543 shares of company stock valued at $47,831,369. Insiders own 10.40% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Fieldpoint Private Securities LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth $130,000. Sterling Investment Advisors Ltd. lifted its holdings in shares of Regeneron Pharmaceuticals by 11.2% during the 2nd quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock worth $137,000 after acquiring an additional 28 shares during the last quarter. FNY Managed Accounts LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth $140,000. FNY Partners Fund LP lifted its holdings in shares of Regeneron Pharmaceuticals by 200.0% during the 2nd quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 200 shares during the last quarter. Finally, Alpha Windward LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 0.3% during the 2nd quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 1 shares during the last quarter. 67.96% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.